Free Trial
NASDAQ:TELO

Telomir Pharmaceuticals 8/13/2024 Earnings Report

Telomir Pharmaceuticals logo
$1.34 -0.15 (-9.80%)
As of 01:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Telomir Pharmaceuticals EPS Results

Actual EPS
-$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Telomir Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Telomir Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Telomir Pharmaceuticals' next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules.

Conference Call Resources

Telomir Pharmaceuticals Earnings Headlines

TELO Makes Progress Toward Human Trials
This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
Telomir Flat on Trial Data Release
See More Telomir Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Telomir Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telomir Pharmaceuticals and other key companies, straight to your email.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals (NASDAQ:TELO), a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

View Telomir Pharmaceuticals Profile

More Earnings Resources from MarketBeat